GSK's drugs arm to get £8 billion booster from spin-off
GSK has set out its plans to turn its consumer healthcare arm into a separately listed company, in a move that will deliver an £8 billion windfall and other financial benefits for its underperforming drugs business.
Business
• 24 Jun 21